Topic Hub
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 8 of 8 clinical reviews.
A clinician-level guide to managing adverse events with PCSK9 inhibitors (evolocumab, alirocumab, inclisiran), covering injection-site reactions, musculoskeletal complaints, neurocognitive concerns, and step-by-step protocols for FH and post-ACS patients.
Read clinical reviewA complete prescriber-level guide to PCSK9 inhibitor drug classes, FDA-approved agents, clinical evidence, prescribing criteria, and step-by-step prior authorization strategies for evolocumab and alirocumab.
Read clinical reviewA prescriber-level class overview of PCSK9 inhibitors covering mechanism, approved agents, dosing, clinical trial evidence, safety, and 2024 guideline recommendations for FH and post-ACS populations.
Read clinical reviewA complete drug-drug interaction table for PCSK9 inhibitors (evolocumab, alirocumab, inclisiran), plus class pharmacology, dosing, and prescribing guidance for FH and post-ACS patients.
Read clinical reviewA board-reviewed clinical guide covering the PCSK9 inhibitor drug class, prescribing criteria, lipid and safety monitoring schedules, dose adjustments, and real-world outcomes data for evolocumab and alirocumab.
Read clinical reviewA prescriber-level review of PCSK9 inhibitor use across special populations including familial hypercholesterolemia, post-ACS patients, chronic kidney disease, diabetes, elderly patients, and pregnancy, with dosing guidance and key trial data.
Read clinical reviewA prescriber-level guide to choosing between evolocumab, alirocumab, and inclisiran for FH, post-ACS, and statin-intolerant patients. Covers mechanism, dosing, trial data, payer hurdles, and a practical selection framework.
Read clinical reviewA clinician-level guide to PCSK9 inhibitor drug class review, dosing titration, tapering strategies, and prescribing algorithms for FH and post-ACS patients, reviewed by the HealthRX medical team.
Read clinical review